QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
QurAlis has raised $88.0M in total funding. The most recent round was Series B. The last funding was announced in March 2023.
QurAlis's investors include Sanofi Ventures, Polaris Partners, Dementia Discovery Fund, EQT Life Sciences, Alexandria Venture Investments.
QurAlis is headquartered in Cambridge, United States.
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
QurAlis is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"QurAlis — Funding & Investors." VCBacked, March 9, 2023, https://www.vcbacked.co/company/quralis. Accessed November 14, 2026.
VCBacked. (2023). QurAlis — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/quralis
{{cite web |title=QurAlis — Funding & Investors |url=https://www.vcbacked.co/company/quralis |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at QurAlis? Request a listing update